K777 is a potent, orally active and irreversible inhibitor of cysteine protease. K777 is a potent CYP3A4 inhibitor (IC50= 60 nM). K777 is also a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, which is the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 targets cathepsin-mediated cell entry and wxibits a broad-spectrum antiviral activity. K777 inhibits EBOV and SARS-CoV pseudovirus entry with IC50 values of 0.87 nM and 0.68 nM, respectively.

4-APC hydrobromide is a potent and specific aldehyde derivatization agent. It contains an aniline moiety that enables rapid and selective reaction with aliphatic aldehydes, as well as a quaternary ammonium group that enhances sensitivity in mass spectrometry (MS) analysis. By utilizing 4-APC hydrobromide, aldehydes can be detected with exceptional sensitivity and selectivity using MS.

APC-366 is a selective inhibitor of the mast cell tryptase that inhibits tryptase-induced histamine release from human tonsil and lung cells.

APC-3316 tosylate is a vinyl sulfone cysteine protease inhibitor and selective CCR4 antagonist.

APC-3316 hydrochloride is a vinyl sulfone cysteine protease inhibitor and selective CCR4 antagonist.

APC 366 (TFA) is a potent irreversible inhibitor of mast cell tryptase. It is particularly useful in studies related to allergic diseases.

APC 366 is a selective inhibitor of mast cell tryptase with Ki of 7.1 μM. APC 366 inhibits antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma [1] [2].

APC-6336 is a bio-active chemical.

APC-0576 is an (S,S)-isomer which inhibits NF-kappaB-dependent gene activation. APC-0576 may prevent pro-inflammatory cytokine-induced chemokine production in human endothelial cells.

APC-6860 is a trypsin-like serine proteases inhibitor with k i values of 0.21, 0.44, 1.5, 16.8, 20, 30 μM for uPA, trypsin, tryptase, tPA, thrombin and factor Xa, respectively. APC-6860 has a selectivity ratio for tPA versus uPA of 80. APC-6860 has k i values of 0.1, 0.082 μM for human and murine urokinases, respectively. APC-6860 can be used for the research of cancer.

Apcin A HCL is an Apcin derivative. Apcin A HCL is an anaphase-promoting complex (APC) inhibitor. Apcin-A HCL interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A HCL can be used to synthesize the PROTAC CP5V (HY-130

RPR121056 is a Irinotecan metabolite, which is generated by CYP3A4. Irinotecan is an antineoplastic agent that inhibits topoisomerase type I.

TAME hydrochloride (Tos-Arg-OMe HCl) is a kind od amino acid derivatives.

DHAPC (1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine) can be used as a fluorine-18 radiolabeling agent for PET imaging of prostate cancer.

Bibapcitide, a 26-amino-acid peptide, acts as a thrombosis inhibitor [1].

Activated Protein C (390-404), human acetate (Activated Protein C ) inhibits APC anticoagulant activity.

TASIN-1 Hydrochloride (TASIN-1 HCl) is a selective inhibitor of truncated APC that acts by selectively killing colorectal cancer cells that express truncated APC by reducing cellular cholesterol levels and inducing apoptotic cell death through the ER stress/ROS/JNK signaling in colon cancer cells.

ProTAME is an inhibitor of APC/CFzr and APC/CCdc20. Combinations of proTAME with topoisomerase inhibitors, doxorubicin and etoposide, significantly increase cell death in primary cells and Multiple Myeloma (MM) cell lines, particularly if TOPIIα levels are first increased through pre-treatment with ProTAME.This compound is unstable in powder form and other related salt forms are recommended.

Apcin-A is an anaphase-promoting complex (APC) inhibitor. It interacts strongly with Cdc20 and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V.

Apcin is a potent and competitive inhibitor of anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. It acts by blockin

DMHAPC-Chol is a cationic cholesterol. Liposomes containing DMHAPC-chol have been used for DNA plasmid delivery in vitro and in vivo in a B16-F10 mouse xenograft model. Liposomes containing DMHAPC-chol are cytotoxic to B16-F10 cells when used at lipid concentrations greater than 20 μM. DMHAPC-Chol, as part of a lipoplex with DOPE , has also been used to deliver DNA into mouse lung via intratracheal injection, resulting in a heterogeneous distribution in the bronchi and bronchioles, and to deliver VEGF siRNA into A431 and MDA-MB-231 cells, which secrete VEGF.

HAPC-Chol is a cationic cholesterol. HAPC-Chol, as part of a lipoplex with DOPE , has been used for siRNA delivery and gene silencing in MCF-7 cells in a luciferase assay without affecting cell viability. It has also been used to deliver siRNA into mice via intravenous injection, resulting in HAPC-chol accumulation in the lungs.

APcK110 is a novel Kit inhibitor . APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI/AML3 in a dose-dependent manner . APcK110 is a more potent inhibitor of OCI/AML3 proliferation than the clinically used Kit inhibitors imatinib and dasatinib and at least as potent as cytarabine. APcK110 inhibits the phosphorylation of Kit, Stat3, Stat5, and Akt in a dose-dependent fashion, showing activity of APcK110 on Kit and its downstream signaling pathways . APcK110 may have potent application in AML.

MHAPC-Chol is a cationic cholesterol. MHAPC-Chol, as part of a lipoplex with DOPE , has been used for siRNA delivery and gene silencing in MCF-7 cells in a luciferase assay without affecting cell viability. It has also been used to deliver siRNA into mice via intravenous injection, resulting in MHAPC-chol accumulation in the liver.

DYSP-C34, a potent ultrasound (US)-triggered multifunctional molecular machine, exhibits a favorable lipophilic/hydrophilic balance, enhanced US-induced reactive oxygen species (ROS) production, and improved cellular permeability. These properties contribute to its superior tumor-targeting efficiency and significant tumor regression when used in sonodynamic therapy (SDT). Additionally, DYSP-C34 demonstrates mild immunogenicity by directly stimulating antigen-presenting cells (APCs) [1].

MAIT-203, a cyclopentyalanin-derived peptidomimetic, effectively disrupts the interaction between adenomatous polyposis coli (APC) and Asef (RhoGEF4), without affecting APC-Sam68 or APC-striatin interactions. It binds to APC-ARM domains with a K i of 0.015 μM and a K d of 0.036 μM, and notably inhibits the migration and invasion of colorectal cancer cells.

Drotrecogin alfa (activated) (DrotAA), a recombinant human activated protein C (APC), mitigates smoke-induced elevations in pulmonary microvascular permeability and proinflammatory cytokine IL-1β levels in rats. It also inhibits coagulation and inflammation while enhancing fibrinolysis. Drotrecogin alfa (activated) is applicable in severe sepsis research [1] [2].

Inhibits interaction of APC and Asef (RhoGEF4). Inhibits colorectal cancer cell migration and invasion in vitro.

TASIN-1 is a small molecule inhibitor of mutant adenomatous polyposis coli (APC).

Activated Protein C (390-404), human, a peptide derived from the vitamin K-dependent serine protease, effectively suppresses the anticoagulant activity of APC[1].

CFM-1 is an antagonist of the anaphase-promoting complex (APC)-2. It also is a cell cycle and apoptosis regulatory protein (CARP)-1 interaction antagonist.

CFM 4 is a potent small molecule CARP-1/APC-2 antagonist that prevents CARP-1 from binding to APC-2, contributes to G2M cell cycle arrest, and induces apoptosis, with an IC50 in the range of 10-15 μM.CFM 4 inhibits the growth of drug-resistant human breast cancer cells.

Danicopan (ACH-4471) (ACH-4471) is a selective, orally active small molecule factor D inhibitor with high binding affinity to human factor D, with a Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits the activity of the complement replacement pathway (APC) and may block the complement replacement pathway in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

JW 67 is an inhibitor of canonical Wnt pathway signaling. JW 67 rapidly reduced active β-catenin with a subsequent downregulation of Wnt target genes, including AXIN2, SP5, and NKD1.

KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.

Unesbulin (PTC596) is an orally active and selective inhibitor of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1).

KYA1797 is an inhibitor of the Wnt/ß-catenin pathway. KYA1797 binds directly to the regulators of G-protein signaling domain of axin, initiats ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effecti

CRA-2059 hydrochloride is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ)[1][2]. Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 hydrochloride has the potential for inflammatory bowel disease research[1]. [1]. Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002;16(3):407-413.[2]. Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384(12):1605-1611.

Tosyl-L-Arginine Methyl Ester (TAME (N-4-Tosyl-L-arginine methyl ester)) is an APC inhibitor.

CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ)[1][2]. Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 has the potential for inflammatory bowel disease research[1]. [1]. Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002;16(3):407-413.[2]. Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384(12):1605-1611.

ONO-1714 is a inducible nitric oxide synthase (NOS-2) inhibitor. ONO-1714 reduces hyperoxic lung injury in mice. ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice. ONO-1714 also inhibits neuronal NOS and exerts an

The peptide region containing residues 390-404 in Activated Protein C (APC) is essential for anticoagulant activity and is available for interaction with antibodies or with other proteins, such as the macromolecular substrates Factors Va or VIIIa. APC reg

D-Lys(Z)-Pro-Arg-pNA is a luminescent substrate of activated protein C (APC).

Eftilagimod alfa (IMP321), a recombinant LAG-3Ig fusion protein, binds to MHC class II and mediates the activation of antigen-presenting cells (APCs), which in turn activates CD8 T-cells. It is utilized in the research of metastatic melanoma and metastatic breast carcinoma [1].

NC-2100 is an aperoxisome proliferator-activated receptor-gamma (PPARgamma) activator.

IMP-321 is a soluble dimeric recombinant form of LAG-3 and first-in-class antigen presenting cell activator.